598 related articles for article (PubMed ID: 33403858)
21. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases.
Chen C; Borrego ME; Roberts MH; Raisch DW
Expert Opin Drug Saf; 2019 Aug; 18(8):733-744. PubMed ID: 31173698
[No Abstract] [Full Text] [Related]
22. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
23. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
24. Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study.
Li X; Chen G; Hu Y; Zhao B; Jiang J
Anticancer Drugs; 2022 Jan; 33(1):e228-e234. PubMed ID: 34538863
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
26. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Sato K; Mano T; Iwata A; Toda T
Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
28. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
29. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
Poluzzi E; Raschi E; Koci A; Moretti U; Spina E; Behr ER; Sturkenboom M; De Ponti F
Drug Saf; 2013 Jun; 36(6):467-79. PubMed ID: 23553446
[TBL] [Abstract][Full Text] [Related]
30. PEGylated versus non-PEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting System (FAERS) Database
.
Zhu Z; Gao P; Hu Y; Wang J; Wang H; Yang J; Huang L; Ji C; Ni Y; Fang L
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):332-342. PubMed ID: 32324132
[TBL] [Abstract][Full Text] [Related]
31. Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis.
Aboukaoud M; Wilf-Yarkoni A; Maor E
Epilepsia; 2023 Sep; 64(9):2322-2329. PubMed ID: 37350356
[TBL] [Abstract][Full Text] [Related]
32. Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years.
Andreaggi CA; Novak EA; Mirabile ME; Sampathkumar S; Gray MP; He M; Kane-Gill SL
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1627-1635. PubMed ID: 32851782
[TBL] [Abstract][Full Text] [Related]
33. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
35. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
36. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
37. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
39. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
40. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]